BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity

Authors:

Abstract
Key Points: The V600E kinase-activating mutation of BRAF profoundly shapes the distinct identity of HCL among B-cell neoplasms. Clinically available BRAF and MEK inhibitors exert potent antileukemic activity in patients’ HCL cells in vitro and in vivo.

This publication has 30 references indexed in Scilit: